Table 2. Breast Cancer Stage, Past Treatment for Breast Cancer, Source of Stem Cells, and Auto HSCT Protocol.
| Variables | Category | Johns Hopkins Oncology Center (n=16) | Lombardi Cancer Center (n=16) | Total (N=32) | |||
|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | ||
| Breast Cancer | |||||||
| Stagea | Stage II | 8 | 57.1 | 7 | 43.8 | 15 | 50.0 |
| Stage III | 6 | 42.9 | 4 | 25.0 | 10 | 33.3 | |
| Stage IV | 0 | 0.0 | 5 | 31.3 | 5 | 16.7 | |
| Past Treatment | |||||||
| Surgery+Chemotherapy | 14 | 87.5 | 12 | 75.0 | 26 | 81.3 | |
| Surgery+Chemotherapy+RT | 1 | 6.25 | 2 | 12.5 | 3 | 9.4 | |
| Surgery+CTb +RTc +HTd | 0 | 0.0 | 1 | 6.3 | 1 | 3.1 | |
| SXe +CT+HT | 1 | 6.3 | 1 | 6.3 | 2 | 6.3 | |
| Surgery Type | |||||||
| Lumpectomy | 1 | 6.3 | 0 | 0.0 | 1 | 3.1 | |
| Lumpectomy+ALND f | 3 | 18.8 | 7 | 43.8 | 10 | 31.3 | |
| MRMg | 3 | 18.8 | 0 | 0.0 | 3 | 9.4 | |
| MRM+ALND | 3 | 18.8 | 2 | 12.5 | 5 | 15.6 | |
| MRM+Reconstruction | 2 | 12.5 | 4 | 25.0 | 6 | 18.7 | |
| Bilateral Mastectomy+Rh | 1 | 6.3 | 1 | 6.3 | 2 | 6.3 | |
| MRM+ALND+SMi | 0 | 0.0 | 1 | 6.3 | 1 | 3.1 | |
| MRM+ALND+R | 3 | 18.8 | 1 | 6.3 | 4 | 12.5 | |
| Chemotherapy | |||||||
| Adriamycin+Cytoxan+Taxol | 10 | 62.5 | 11 | 68.7 | 21 | 65.6 | |
| Adriamycin+Cytoxan | 3 | 18.8 | 0 | 0.0 | 3 | 9.4 | |
| NeoTaxolj +Adria+Cytoxan | 0 | 0.0 | 3 | 18.7 | 3 | 9.4 | |
| Cytoxan+Adria+ 5-FU k | 1 | 6.3 | 0 | 0.0 | 1 | 3.1 | |
| Adriamycin+Taxotere | 1 | 6.3 | 0 | 0.0 | 1 | 3.1 | |
| Cytoxan+MTXl +5-FU+ Taxotere+Adriamycin | 0 | 0.0 | 1 | 6.3 | 1 | 3.1 | |
| Adriamycin+Cytoxan+ 5-FU+Taxol | 0 | 0.0 | 1 | 6.3 | 1 | 3.1 | |
| Adriamycin+Taxol+5-FU | 1 | 6.3 | 0 | 0.0 | 1 | 3.1 | |
| Hormonal Agent Stem Cell Source | Tamoxifen | 1 | 6.3 | 2 | 12.5 | 3 | 9.4 |
| Bone Marrow (BM) | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
| Peripheral Blood | 12 | 75.0 | 16 | 100.0 | 28 | 87.5 | |
| BM and Peripheral Blood | 4 | 25.0 | 0 | 0.0 | 4 | 12.5 | |
| HSCT Protocol | |||||||
| JH9819 | 14 | 87.5 | 0 | 0.0 | 14 | 43.7 | |
| JH9534 | 2 | 12.5 | 0 | 0.0 | 2 | 12.5 | |
| 97-311 | 0 | 0.0 | 14 | 87.5 | 14 | 43.7 | |
| LCCBMT | 0 | 0.0 | 2 | 12.5 | 2 | 12.5 | |
n=30;
CT=chemotherapy;
RT=radiation therapy;
HT=hormonal therapy;
SX=surgery;
ALND=axillary lymph node dissection;
MRM=modified radical mastectomy;
R=reconstruction;
SM=simple mastectomy;
Neo=neoadjuvant;
5-FU=5-fluoruracil;
MTX=methotrexate.
JH9819=cyclophosphamide 1.5g/m2/day, thiotepa 125mg/m2/day, carboplatin 200mg/m2/day via continuous infusion (CI) BMT day -8 to -4, cyclosporine A 2.5mg/kg/day/IV BMT day 0 to+28, gamma interferon 0.025mcg/m2 SQ QOD BMT day +7 to +28; JH9534=cyclophosphamide 1.5g/m2/day and thiotepa 200mg/m2/day via CI BMT day -8 to -4, cyclosporine A 2.5mg/kg/day/IV BMT day +7 to BMT day +28, gamma interferon 0.025mcg/m2 SQ QOD BMT day +7 to +28, and IL-2 beginning at 104 U/m2/day SQ; 97-311: STAMP V-cyclophosphamide 1500mg/m2/day, thiotepa 125mg/m2/day, carboplatin 200mg/m2/day CI BMT day -7 to -4, IL-2 5 days on, 2 days/weekly, recombinant HGCSF 5mcg/kg SQ QD BMT day +5 until AGC >5,000/mm3; LCCBMT: Stamp V.